Martin Babler

South San Francisco, California, United States
Martin Babler is Alumis’s Chief Executive Officer, President, and Chairman of the Board since September 2021. Prior to joining Alumis, he served as President and Chief Executive Officer of Principia Biopharma, until its acquisition by Sanofi S.A. in October 2020. Prior to joining Principia Biopharma, Martin served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. From 1998 to 2007, he held several positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. While at Genentech, he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Martin previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. He presently serves on the Board of Directors of Neoleukin Therapeutics, Inc., Prelude Therapeutics Inc., Omega Alpha SPAC, Sardona Therapeutics and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Martin received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Speaking In
3:00 PM - 4:00 PM (PDT)
Tuesday, June 14
Biotech brought the world innovation and cures and helped things get back to the new normal…